Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FLKS

Flex Pharma (FLKS) Stock Price, News & Analysis

Flex Pharma logo

About Flex Pharma Stock (NASDAQ:FLKS)

Key Stats

Today's Range
$1.70
$1.78
50-Day Range
$0.57
$14.51
52-Week Range
$0.26
$1.49
Volume
29,922 shs
Average Volume
2.03 million shs
Market Capitalization
$30.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive FLKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter.

FLKS Stock News Headlines

FLEX LNG Ltd. (FLNG) Q2 2024 Earnings Call Transcript
Elon Musk: my AI will be “worth more than Tesla”
Tesla made Elon Musk the richest man in human history. And now, Elon's got a new AI project...
Wayfair Inc. (W) Q2 2024 Earnings Call Transcript
Q2 2024 AGCO Corp Earnings Call
Flex Ltd. (FLEX) Q1 2025 Earnings Call Transcript
Flex Ltd.: Undervalued With Solid Fundamentals
See More Headlines

FLKS Stock Analysis - Frequently Asked Questions

Flex Pharma Inc (NASDAQ:FLKS) posted its quarterly earnings results on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company had revenue of $0.11 million for the quarter. Flex Pharma had a negative trailing twelve-month return on equity of 98.04% and a negative net margin of 1,208.42%.

Flex Pharma (FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flex Pharma investors own include Micron Technology (MU), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Gilead Sciences (GILD) and Histogenics (HSGX).

Company Calendar

Last Earnings
5/01/2019
Today
1/08/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLKS
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-21,920,000.00
Net Margins
-1,208.42%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$840,000.00
Book Value
$0.51 per share

Miscellaneous

Free Float
N/A
Market Cap
$30.90 million
Optionable
Not Optionable
Beta
1.65
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FLKS) was last updated on 1/8/2025 by MarketBeat.com Staff
From Our Partners